Evidence map›Paper›PMID 34283410›Full record

ArticleAging clinical and experimental research2022

Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment.

Wataru Araki, Kazutomi Kanemaru, Kotaro Hattori, Tadashi Tsukamoto, Yuko Saito, Sumiko Yoshida, Harumasa Takano, Masuhiro Sakata, Yuma Yokoi, Yoshie Omachi and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Aging clinical and experimental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wataru ArakiDepartment of Demyelinating Disease and Aging, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), 4-1-1 Ogawahigashi, Kodaira, Tokyo, 187-8502, Japan. wataruara@yahoo.co.jp.ORCID http://orcid.org/0000-0001-8467-6937
Kazutomi KanemaruTokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan.
Kotaro HattoriMedical Genome Center, NCNP, Kodaira, Tokyo, Japan.
Tadashi TsukamotoNational Center Hospital, NCNP, Kodaira, Tokyo, Japan.
Yuko SaitoNational Center Hospital, NCNP, Kodaira, Tokyo, Japan.
Sumiko YoshidaNational Center Hospital, NCNP, Kodaira, Tokyo, Japan.
Harumasa TakanoNational Center Hospital, NCNP, Kodaira, Tokyo, Japan.
Masuhiro SakataNational Center Hospital, NCNP, Kodaira, Tokyo, Japan.
Yuma YokoiNational Center Hospital, NCNP, Kodaira, Tokyo, Japan.
Yoshie OmachiNational Center Hospital, NCNP, Kodaira, Tokyo, Japan.
Utako NagaokaTokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.
Masahiro NagaoTokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.
Takashi KomoriTokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.
Hisateru TachimoriDepartment of Clinical Epidemiology, Translational Medical Center, NCNP, Kodaira, Tokyo, Japan.
Shigeo MurayamaTokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan.
Hidehiro MizusawaNational Center Hospital, NCNP, Kodaira, Tokyo, Japan.

Funding

National Center of Neurology and Psychiatry (JP) 30-3
6 · The paper itself

Abstract

objectivesConcentrations of soluble amyloid precursor proteins-α (sAPPα) and -β (sAPPβ) in cerebrospinal fluid (CSF) may reflect the neuropathology of Alzheimer's disease (AD). We previously reported that the concentrations of both sAPPα and sAPPβ were significantly higher in patients with mild cognitive impairment (MCI) due to AD (MCI-AD) than in control subjects without cognitive impairment. The present study analyzed whether these sAPPs are useful in the differential diagnosis of MCI.

methodsA modified and sensitive method was used to analyze concentrations of sAPPα and sAPPβ in CSF of patients with MCI-AD (n = 30) and MCI due to other causes (MCI-others) (n = 24). Phosphorylated tau (p-tau) and amyloid β-protein 42 (Aβ42) were also analyzed using standard methods.

resultsCSF concentrations of sAPPα and sAPPβ were significantly higher in the MCI-AD than in the MCI-others group (p < 0.001). Furthermore, concentrations of both sAPPα and sAPPβ were highly correlated with the concentration of p-tau, consistent with our previous report.

conclusionsMeasurement of both sAPPs in CSF using sensitive methods can be helpful in the precise differential diagnosis of patients with MCI.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBiomarkersDiagnosis, DifferentialHumansPeptide Fragmentstau ProteinsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAPP protein, humanBiomarkersPeptide Fragmentstau ProteinsAlzheimer’s diseaseBiomarkerCerebrospinal fluidMild cognitive impairmentSoluble amyloid precursor proteinTau

Identifiers

PMID34283410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.